Numerous large clinical trials have demonstrated the benefit of implantable cardioverter-defibrillators (ICDs) to prevent sudden cardiac death (SCD) in selected populations.
of an S-ICD shock configuration with that of a conventional TV-ICD respectively. The mean time to shock delivery was 14.0±2.5 seconds, whereas the mean procedure duration was 67±33 minutes. After 10±1 months of follow-up, a total of 12 episodes of clinical ventricular arrhythmia were detected and terminated effectively by the S-ICD.
Minor complications were observed in five patients (pocket infection in two patients, parasternal subcutaneous lead dislodgement in three patients). Oversensing and inappropriate sensing were rare (double counting, muscle noise) and were managed by device reprogramming.
The S-ICD System
The system consists of a subcutaneous PG and a subcutaneous lead placed along the left side of the sternum. The first PG generation (model SQ-RX 1010, Cameron Health, Inc.) has a volume of ~70 cc, a weight of 145 g and a projected longevity of 5 years. The subcutaneous lead is provided with two sensing electrodes separated by an 8 cm shock coil.
Using these sensing electrodes and the generator itself as the third one, three sensing vectors are available to detect the subcutaneous signals.
The best vector is automatically selected by the system in order to avoid double QRS counting and T-wave oversensing. In this regard, a screening tool is used before implantation to confirm patients' eligibility to the S-ICD by analysing the surface electrocardiogram (ECG) signals in both supine and standing positions (see Figure 1 ).
The implantation procedure is basically guided by anatomical landmarks with the option of fluoroscopy check to confirm optimal shock vector crossing the heart silhouette. At the end of the procedure, VF is induced using 50 Hz to assess correct detection and defibrillation (at 65 J) of the arrhythmia. Unlike the TV-ICD, the defibrillation test is still mandatory in the S-ICD since defibrillation threshold may be more dependent on the system positioning with fewer available long-term follow-up data.
Sensing the Subcutaneous Signals and Tachyarrhythmia Detection
Three sensing vectors are available in the S-ICD (see Figure 1) ; primary:
sensing from the proximal electrode ring on the subcutaneous lead to the active surface of the PG; secondary: sensing from the distal sensing electrode ring on the subcutaneous lead to the active surface of the PG; and alternate: sensing from the distal sensing electrode ring to the proximal sensing electrode ring on the subcutaneous lead.
Based on signal/noise and QRS/T ratios, the system automatically selects the best sensing vector to provide appropriate detection.
Automatic analysis of sensed signals basically includes three consecutive phases to avoid inappropriate sensing. 1) Detection phase: the device uses a detection threshold that is automatically adjusted continuously using amplitudes of recently detected events.
2) Certification phase during which the system excludes suspected events such as noise/artifacts, double QRS counting or T wave oversensing. 3) Decision phase: after excluding suspected events, only certified events are continuously analysed to calculate a running four R-R interval average, which is the indicator of heart rate.
In the shock zone (programmable between 170 and 250 bpm), rate is the only criterion used to determine if a rhythm will be treated with a shock. On the other hand, the optional conditional shock on the safety and efficacy of the S-ICD in primary and secondary prevention of SCD, and in different cardiac etiologies (see Table 1 ).
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The most available data on the S-ICD performance were obtained through pooled data from two large registries: IDE (S-ICD System
IDE Clinical investigation) and EFFORTLESS (Boston Scientific Post
Market S-ICD Registry). 26 Data from these registries were recently published analysing S-ICD performance in 882 patients followed for 21.7±11.5 months.
The incidence of appropriate shock was 5. 3,4,27 The pooled S-ICD cohort included relatively younger patients (~50 years), mainly with primary prevention indication (~70 %), and more than 20 % prevalence of channelopathies, electrical and genetic heart disease. 26 Another important factor to be considered is the setting of ICD therapies. The incidence of appropriate therapy in the S-ICD was somewhat similar to that in the Sudden Cardiac Death in Heart Failure Trial (SCD-Heft) trial. 1 The latter trial was conducted in patients with primary prevention indication (ejection fraction [EF] <35 %) and the ICD therapy consisted of a single-lead, single-shock zone (>187 bpm) device with no ATP being programmed. 1 This ICD setting mimics the S-ICD design, which aims to treat fast ventricular tachyarrhythmias and has no ATP capability. Indeed, in the pooled S-ICD data the lowest-therapy zone was usually set at 200 bpm, with dual shock zone being activated in about 80 % of patients. 26 The Multicentre Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) trial addressed how the ICD programming may affect the incidence of appropriate therapies. 28 Appropriate ATP therapy occurred in 22 % of patients in the conventional programming arm compared with 8 % and 4 % in the high rate and delayed therapy arms, respectively. However, there was no difference in appropriate shock (5 % with conventional programming or high rate programming, and 4 % with delayed therapy over 1.4 years). This study highlights the fact that conventional 'aggressive' ICD programming may overestimate the real incidence of appropriate therapies by treating potentially non-sustained episodes 'unnecessary therapies'.
Notably, in the S-ICD pooled data about 36 % of detected VT/VF episodes were self-terminated, reflecting a deliberate time-delay strategy and a longer time-to-therapy (~20 seconds). 26 About 90 % of spontaneous VT/VF events were terminated with first shock, and 98.2 % were terminated within the five available shocks. The estimated 3-year device-related complications and allcause mortality were 11.1 % and 4.7 %, respectively. Importantly, no lead failures nor S-ICD related endocarditis/bacteraemia were reported.
Inappropriate shock rate was 13.1 % at 3 years, mostly secondary to T-wave oversensing (about 40 % of inappropriate therapies). In patients with dual-zone programming at the index procedure, the incidence of inappropriate shocks at 3 years was significantly lower (11. 
S-ICD -In Which Patients?
In general terms, all patients with an ICD indication may find in the On the other hand, caution should be taken before considering the S-ICD in patients with a higher probability of developing pacing indications in the near future. These may include patients with significant brady-arrhythmias/conduction defects, and specific cardiomyopathies known to be associated with monomorphic VT which may be pace-terminable. Detailed discussion with patients and families is required to address this issue with a potential future shift to a conventional TV-ICD. The role of an electrophysiology study to evaluate the propensity to a pace-terminable VT, favouring TV-ICD, is still to be determined. Figure 2 highlights the clinical features that may help to select the appropriate ICD technology for each patient. 
How to Reduce Inappropriate Shocks in S-ICD Patients
Inappropriate shocks are a major concern in all ICD systems and are associated with increased mortality and reduced quality of life. 34 Regarding the S-ICD a few considerations should be followed in order to minimise these undesired therapies:
• Prior to implantation: patient screening to ensure adequate transcutaneous signals (pre-operating screening tool) and to exclude those with high probability of double QRS counting/Twave oversensing, which presents the most common cause of inappropriate shocks in S-ICD patients. In one study about 8 % of S-ICD candidates had inadequate transcutaneous signals that were mostly predicted by negative T-waves in lead I and the inferior leads of the surface ECG. 35 • After implantation, sensing optimisation to select the best sensing vector (supine/standing positions).
• Dual zone programming is preferred (e.g. conditional shock zone 190-220 bpm, shock zone >220 bpm) as it was significantly associated with inappropriate shocks reduction in the EFFORTLESS registry.
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• Exercise test may be helpful to evaluate the occurrence of myopotential oversensing/functional bundle branch block during exercise, with the possibility of selecting the best sensing vector and/or to update the QRS template. • Smaller PG size: with a substantial reduction in volume (i15 %, from ~70 to ~60 cc), thickness (3mm less, i20 % from 15.7 to 12.7 mm) and weight (i10 %, from 145 to 130 g).
• Device shape: the edges of the new PG are more rounded and smoother to make its placement in the pocket easier and more comfortable. Furthermore, the header is centred to facilitate the subcutaneous electrode-wrap. These modified physical features of the new generation might be important to reduce patients' discomfort, and importantly, the mechanical stress/skin erosions and thus pocket complications, including haematoma and infections.
• Another important feature of the EMBLEM S-ICD is the longer expected battery longevity (h40 % from 5.1 to 7.3 years). Battery longevity is the determinant factor to reduce replacement interventions that are associated with significant costs and infection risk.
• The new device generation is compatible with remote monitoring (LATTITUDE). This feature might be particularly useful in the S-ICD since there are only a few parameters to be controlled/ programmed allowing the majority of patients to be followed, unless a thorough clinical assessment is required.
• Other technical improvements including the ability to store and print VF induction (defibrillation testing), and Bluetooth pairing/transfer.
Even after 15 years of continuous research and studies, the S-ICD technology is still evolving and the EMBLEM S-ICD represents one of its most recent advances. However, future research and design improvements are still required to address various aspects. For example, a paediatric model of the S-ICD to be used in small children (e.g., < 8 years, < 30 kg) may be an alternative option in the future.
At least theoretically, subcutaneous defibrillation would require lower energies in these subjects due to their small cardiac mass and trans- 
Clinical Perspective
• The S-ICD system represents a viable alternative to TV-ICD for primary and secondary prevention of SCD unless pacing is required.
• Its implantation is less invasive, does not require fluoroscopy and avoids the shortcomings related to TV leads.
• Growing clinical data are available regarding the safety and efficacy of this defibrillation therapy (EFFORTLESS registry).
• Careful patients selection and efforts to minimise inappropriate shocks are essential to optimise the clinical outcome of the S-ICD.
• Those who may particularly benefit from this technology are young patients, those with channelopathies or patients who have already experienced TV lead complications.
• The second-generation S-ICD (EMBLEM) has several favoured features including a smaller PG, longer longevity and remote-monitoring compatibility.
• Further innovations in the S-ICD system, detection algorithms and potential integration with leadless pacing in the future, may make this therapy suitable for a larger cohort of patients at high risk of SCD.
